Vaccination in the elderly: an immunological perspective by Grubeck-Loebenstein, Beatrix et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/copyright
Author's personal copy
Immune senescence special issue. Free access sponsored by the National Institutes of Health
Vaccination in the elderly: an
immunological perspective
Wilbur H. Chen1, Bernard F. Kozlovsky2, Rita B. Effros3, Beatrix Grubeck-
Loebenstein4, Robert Edelman1 and Marcelo B. Sztein1
1Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
3David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
4 Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck 6020, Austria
Successful vaccination of the elderly against important
infectious pathogens that cause high morbidity and
mortality represents a growing public health priority.
Building on the theme of aging and immunosenescence,
we review mechanisms of human immunosenescence
and the immune response to currently licensed vaccines.
We discuss the difficulties in identifying the risk factors
that, in addition to aging, cause immunosenescence and
address the relative paucity of vaccine studies in the
elderly. We conclude that vaccine responses are blunted
in the elderly compared with that of healthy young
adults. However, it is also clear that our understanding
of the mechanisms underlying immunosenescence is
limited and much remains to be learned to improve
the effectiveness of next generation vaccines.
Introduction
The population of persons older than 65 years is expected
to rise dramatically in most areas of the world because of
advances in average life expectancy. Worldwide, the num-
ber of elderly persons is expected to increase from 600
million currently to nearly 2 billion in 2050 and, in devel-
oped countries, 25% of the population will be older than 65.
At the same time, as individuals age, immunosenescence
causes an increased susceptibility to infections, which
results in greater morbidity and mortality compared with
younger adults. Demands on health services will clearly
escalate as a result of this demographic revolution. In
response, successful vaccination against important infec-
tious pathogens of the elderly represents a major preven-
tive strategy that must be emphasized now and in the
future. Unfortunately, immunosenescence not only
impairs the ability to fend off infection but also the capacity
to respond to vaccination. In this article, we will provide a
general discussion on how immunosenescence affects the
quantity and quality of the human response to immuniz-
ation. We will review currently approved vaccines with a
focus on recommendations for their use in the elderly and
discuss current data on vaccine immunogenicity, protec-
tive efficacy and immunological correlates of protection.
We will also briefly discuss some of the lessons we have
learned and what still remains unknown regarding the
effects of aging on the human immune response.
Mechanisms leading to immunosenescence
There is still an ongoing debate among immunologists and
vaccine specialists regarding the optimal vaccine strategy
for the elderly. Whereas neutralizing, opsonizing, hemag-
glutinating, etc. antibodies have been the traditional gold
standards for evaluating vaccine efficacy, it is becoming
increasingly clear that for many pathogens, robust cell-
mediated immunity (CMI) is required for protection. A
second challenge to vaccine development is the hetero-
geneous nature of the target population including age,
history of previous infection, and immune system function.
It is clear that what constitutes a successful vaccine in
infants and young children might differ dramatically from
the features required to protect the elderly. For example,
although influenza immunization of young adults provides
65–80% protection against illness caused by a virus pre-
sent in the vaccine, vaccination of the elderly only affords
30–50% protection against disease [1]. Elderly persons who
fail to mount antibody or CMI responses to the vaccine are
at highest risk, but even those who do respond to vaccina-
tion show a reduced antibody titer and CMI compared with
young individuals.
Given the broad range of responses and degree of pro-
tection afforded the elderly by prophylactic vaccines, there
have been numerous attempts to identify immune system
correlates of successful or unsuccessful vaccination. One
prime example, demonstrated in three recent independent
studies, indicates that poor responsiveness to influenza
vaccination is significantly associated with the presence of
high proportions of a population of CD8+ T lymphocytes
that lack expression of the co-stimulatory molecule CD28
[2–4] (also see the article by Weng et al. in this issue).
Moreoever, associations have been described between high
proportions of CD8+CD28 cells and the prevention of
allograft rejection [5], accelerated progression of HIV-1
infection [6], head and neck tumors [7], cervical cancer
[8], ankylosing spondylitis [9] and other diseases involving
an inflammatory state; suggesting a generalized suppres-
sor function. Of note, this same biomarker is part of a
cluster of immune parameters, the so-called ‘immune risk
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phenotype’, that is associated with early mortality in
longitudinal studies of the elderly [10].
The common theme in many of these reported accumu-
lations of CD8+CD28 T lymphocytes is chronic antigenic
stimulation, be it by virus, alloantigen, autoantigen or
tumor-associated antigen, which stimulates extensive cell
division, ultimately leading to an end stage of irreversible
cell cycle arrest known as replicative senescence. Cell
culture modelling of this process has identified a variety
of characteristics associatedwith CD8+ T lymphocyte repli-
cative senescence [11,12]. These senescent CD8+ T cells are
unable to enter the cell cycle and are resistant to apoptosis
[13], leading to their progressive expansion over time in
vivo [14], which coincides with a loss of CD28 expression
[15] and the ability to upregulate telomerase [16].
The importance of sustained telomerase activity in the
functional changes associatedwith T-cell replicative senes-
cence is underscored by experiments in which the catalytic
component of human telomerase, hTERT, is transduced
into virus-specific CD8+ T cells from HIV-infected persons.
In addition to enhanced proliferative potential and telo-
mere lengthmaintenance, HIV-specific production of inter-
feron-g (IFN-g) and cytotoxicity was significantly increased
[17]. Similar results were obtained using a small molecule
telomerase activator, suggesting that telomerase might
have important immune-enhancing functions in addition
to its specific effects on telomeres [17].
Cell culture kinetic studies on telomerase suggest that
the more rapid loss of telomerase inducibility and CD28
expression in chronically stimulated CD8+ versus CD4+ T
lymphocytes might provide a possible explanation for the
observed preponderance of CD28 T lymphocytes within
the CD8+ subset during aging. Indeed, in many elderly
persons, >50% of the peripheral CD8+ T lymphocyte pool
consists of CD28 cells compared with <20% of these cells
within the CD4+ subset [18]. At least within the CD8+ T-
cell subset, one of the driving forces responsible for gen-
erating the high proportion of cells with a memory, end-
stage phenotype seems to be herpesviruses, which estab-
lish latent infections early in life and persist for many
decades, requiring continuous immunosurveillance [19].
There might be an indirect effect on vaccines caused by
changes in the overall composition of the total T-lympho-
cyte pool. CD8+CD28 T lymphocytes are often part of
oligoclonal expansions that crowd the immunological space
[20,21], a feature that is associated with narrowing of the
available T-cell repertoire [22] (also see the article by
Dowling and Hodgkin in this issue). The poor response
of elderly persons to neoantigens, including vaccine anti-
gens, might be one manifestation of this more restricted
repertoire. Thus, the cost of maintaining immune control
over latent infections is that, by old age, there is a reconfi-
guration of the immune system, leading to reduced
responses to vaccines aimed at preventing acute infections,
particularly those never experienced before. One point that
should be emphasized is that, although priming to neoan-
tigens is defective in the elderly, the recall to booster doses
of an antigen in a previously primed elderly person seems
to remain intact. Antigen specific memory CD4+ or CD8+ T
cells, if elicited when young, persist into old age and can
mediate effective CMI responses [23]. Therefore, aging
seems to differentially affect T-cell function at the naı¨ve
versus memory stages.
Recent evidence also supports the effect of aging on
innate immunity, the first line of host defense (also see
the article by Kovacs and Shaw in this issue). These data
underscore the wide range of immune deficiencies that
might play a role in decreased immune competence associ-
ated with aging.
SENIEUR Protocol for the study of immune responses in
the elderly
Whereas controlling the entire immunological experience
from birth to old age is possible in animal studies, clinical
confirmation of the effects of immunosenescence and the
conduct of vaccine immunological studies in the elderly is
difficult, in large part because of the extremely hetero-
geneous nature of the human population. These variables
include underlying medical conditions, use of medications,
the history of previous infections and exposure to various
unaccountable environmental factors. These multiple con-
founding parameters can have a significant cumulative
effect on immunity, independent of immunesenescence.
Thus, the question becomes, how can these confounding
factors be separated from phenomena directly associated
with immunosenescence?
The most common method is to limit the study popu-
lation to individuals with few or none of these confounding
factors. Because the selection of study participants can be
subjective and to clarify the effect of aging per se on
immune function, strict volunteer selection criteria are
mandatory. Toward this end, the SENIEUR Protocol
was developed in 1984 by the working party of the EUR-
AGE concerted Action Programme on Ageing of the Euro-
pean Community [24,25]. To minimize conflicting results
between studies, the Protocol provides strict admission
criteria for immunogerontological studies (Table 1). Volun-
teers recruited using the SENIEUR Protocol tend to have
more homogeneous immune responses than those not
satisfying the protocol. For example, among elderly that
satisfy the SENIEUR Protocol, interleukin 2 (IL-2) syn-
thesis and T-cell responsiveness to cytokines and exogen-
ous IL-2 were not much different from those observed in
younger adult controls, suggesting that reduced IL-2 pro-
duction is not associatedwith healthy aging [26]. Examples
of exclusion criteria based on nutritional, metabolic,
pharmacologic, demographic and epidemiologic factors will
be discussed later in the section on hepatitis B vaccines.
Aside from minimizing the influence of measurable exter-
nal factors on the immune system, a further advantage of
the SENIEUR Protocol has been its validation by clinical
experience [25].
However, there are several disadvantages of the
SENIEUR Protocol. It requires a time-consuming, labor-
intensive admission workup by highly skilled clinical
research staff. Because only 10–12% of ambulatory,
reasonably healthy elderly persons actually satisfy the
strict SENIEUR admission criteria [24], these individuals
do not accurately reflect the target high-risk population.
The difficulty in identifying and enrolling elderly partici-
pants who do satisfy the SENIEUR Protocol might explain
why only a few vaccination trials have been conducted
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under its strict guidelines (i.e. Haemocyanin [27], tetanus
[28,29] and influenza [30–32] vaccines). The remainder of
elderly clinical vaccine trials have opted to use looser
eligibility criteria, making the specific effect of immune-
senescence difficult to dissociate from potential confound-
ing and biasing factors that are independent of age [23].
With these caveats in mind, we will now review some of the
prevailing data on the effect of age on the immunogenicity
and efficacy of specific vaccines.
Pneumococcal vaccine
Infections caused by Streptococcus pneumoniae account for
25–35% of bacterial pneumonias resulting in hospitaliz-
ation and thus remain a significant cause of morbidity and
mortality in the elderly [33]. The current pneumococcal
polysaccharide vaccine (PPV) was licensed in 1983 and is
recommended for all individuals 65 years of age and
those 18–64 years of age at risk for pneumococcal infection.
This vaccine incorporates 23 pneumococcal serotypes in-
cluding the 6 (6B, 9V, 14, 19A, 19F and 23F) most fre-
quently causing invasive drug-resistant infection in the
United States. The current recommendation is for PPV to
be administered once to anyone 65 years of age, and only
oncemore if they had received PPV at age< 65 years and if
it has been 5 years since that first dose.
Although the efficacy of PPV was convincingly demon-
strated in the 1970s by randomized, controlled trials in
younger adults, the data for efficacy in elderly adults are
not as persuasive. One problem with attempts to compare
the efficacy of PPV in the elderly has been the dissimilarity
of the study populations; in some studies, frail elderly
subjects with significant comorbidities are included,
whereas in others, only healthy elderly are studied, but
none used the SENIEUR Protocol [34]. Another important
variable among these clinical studies is the definition of the
outcome variable of interest (e.g. lower respiratory tract
infection, pneumonia-related death, or all-cause
mortality). A further set of confounding factors relates to
different criteria used to define pneumococcal disease (i.e.
pneumonia defined by clinical symptoms alone, clinical
symptoms with radiographic confirmation and confir-
mation using different culture and detection methods of
various body samples, each having a different sensitivity
and specificity for S. pneumoniae). Despite this variability,
the cumulative data indicate a decreased PPV efficacy in
immunocompromised hosts and waning vaccine efficacy
with increasing age [35].
Although PPV afforded protection against blood cul-
ture–proven invasive pneumococcal disease, prospective
randomized controlled trials [36,37], large cohort studies
[38] and numerousmeta-analyses [39] have failed to reveal
a protective effect in the elderly against non-bacteremic
pneumococcal pneumonia. On the whole, these data sup-
port the use of PPV in the elderly to prevent bacteremic
pneumonia but also highlight the need for further vaccine
research to prevent non-bacteremic pneumococcal disease.
The current and most accepted immunological correlate
of protection of pneumococcal vaccines is based on the
elicitation of antibodies against serotype-specific pneumo-
coccal capsular polysaccharide, which facilitates opsono-
phagocytosis (Box 1). A greater than twofold increase in
serotype-specific opsonophagocytosis assay (OPA) anti-
body usually develops within 2–3 weeks in healthy adults,
but the OPA antibody level that correlates with protection
Table 1. SENIEUR protocol: inclusion and exclusion criteria for admission to immunogeriatic studiesa.
Inclusion criteria
1. Men and women 65 years of age or older
2. Community dwelling
3. Stable chronic non–immunologically mediated conditions (e.g. osteoarthritis, hypertension)
4. Normal range of reference laboratory for complete blood count and differential, thyroid-stimulating hormone, serum vitamin B12, folate,
vitamin E, aspartate aminotransferase/serum glutamate-oxaloacetate transaminase and alanine aminotransferase/serum glutamic pyruvate
transaminase, albumin, fasting blood glucose, blood urea nitrogen and serum creatinine
Exclusion criteria
1. History or clinically apparent immunologically mediated chronic conditions (e.g. rheumatoid arthritis, lupus erythematosus)
2. Immunodeficiency
3. Severe respiratory disease requiring supplemental oxygen
4. Psychiatric disorder, untreated or not in remission
5. Infection within 2 weeks of immunization
6. Inflammatory processes such as known chronic infections, inflammatory bowel disease or Westergren sedimentation rate (>50 mm/h for men,
>60 mm/h for women)
7. All malignancies (excluding nonmelanotic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years
8. Arteriosclerotic event during the 2 weeks before enrollment (e.g. medically documented myocardial infarction, stroke, recanalization of the
femoral arteries, claudication, or transient ischemic attack)
9. Cardiac insufficiency, if heart failure present (New York Heart Association functional class III or IV)
10. Poorly controlled hypertension (systolic blood pressure 180 mmHg, diastolic blood pressure 100 mmHg)
11. Renal Insufficiency (serum creatinine 2.0 or blood urea nitrogen 40)
12. Elevated or low glucose (fasting 140 or <70; nonfasting >200)
13. Cognitive impairment: score of <23 on the Folstein Mini-Mental State Examination.
14. Depression or mood alteration: score of 6 on the Geriatric Depression Scale (ref)
15. Malnutrition as defined by clinical judgment and by decreased serum albumin (<3.2 g/l) or hypercholesterolemia (<160 mg/dl), or low
total lymphocyte count (<1500/ml3).
16. Anemia (Hct <30% or low serum vitamin B12, folate or vitamin E level)
17. History of or current alcoholism or consuming >2 oz of ethyl alcohol/d; current drug abuse; currently smoking 10 cigarettes./d.
18. Medication exclusions include prednisone >5 mg/d (or equal), colchicines, imuran, methotrexate, azathioprine, cyclophosphamide,
cyclosporine, or interferons.
aAdapted by Edelman from Ligthart [24]).
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has not been clearly defined. Although PPV responses
might not be consistent among all 23 vaccine serotypes,
antibody levels are lower in the elderly and in those with
chronic disease [33,41]. On the other hand, healthy elderly
adults 75 years of age (modified SENIEUR protocol),
compared with adults 35 years of age, are able to elicit
similar serotype-specific antibodies and antibody avidity
after PPV vaccination [34]. The antibody response induced
by PPV, because it is a polysaccharide and lacks a protein
carrier, is a T lymphocyte–independent response, lacking
immunological memory and the ability to mount a booster
effect. As a result, revaccination after a second dose of PPV
in persons 65 years of age is not recommended because
the data for safety and immunogenicity are not conclusive.
By contrast, polysaccharide conjugate vaccines (PCVs, only
licensed for pediatric use), which elicit T lymphocyte–de-
pendent responses, result in increased immunogenicity,
memory and a booster effect in infants [42]. The single
study, to our knowledge, which evaluated the immuno-
genicity of PCV versus PPV in vaccine-naı¨ve elderly, found
that a 7-valent PCV was more immunogenic than PPV and
elicited a booster response to a subsequent vaccination 1
year later [43].
In conclusion, further research is necessary for the de-
velopment of a more effective means to prevent non-bac-
teremic pneumococcal pneumonia, especially for the
elderly. Perhaps newer polysaccharide conjugate or
protein-based (non-polysaccharide) pneumococcal vaccines
will demonstrate stronger evidence of protection in the
elderly.
Influenza vaccine
Influenza virus infections account for up to 430 000 hos-
pitalizations and 20 000–40 000 deaths annually in the
United States, among which >90% of the mortality occurs
in the elderly population. These figures underscore the
urgent need for more effective methods of primary preven-
tion of influenza infection. The current influenza vaccines
approved for use in the elderly consist of trivalent inacti-
vated subvirions; purified viral components, containing
15 mg of hemagglutinin from the three representative virus
strains that are believed to be themajor circulating strains
for the particular influenza season (currently types H1N1,
H3N2 and B), are obtained from viruses grown from
pathogen-free embryonated chicken eggs. Annual vaccina-
tion is recommended during the fall and early winter for all
persons 50 years of age.
Although data on influenza vaccine effectiveness in the
elderly is somewhat controversial, several estimates
suggest that vaccination reduces influenza-specific hospi-
talization by 27–45% and death by 43–50% [1,44–47]. By
contrast, the efficacy, prevention of laboratory-confirmed
influenza, of the same influenza vaccines among young
adults is 70–90% [48]. There are few randomized controlled
trials that include the elderly, and the existing observa-
tional studies have been criticized for methodological pro-
blems including inadequate consideration of potential bias;
frailty among the heterogeneous elderly population; varia-
bility in the serological match between the vaccine virus
strains and the circulating influenza strains and the use of
outcome measures with low sensitivity (influenza-like ill-
ness rather than laboratory confirmed influenza). These
methodological issues inherent in cohort studies have led
to overestimates of efficacy [49] and also suggest that
vaccination might not be reducing influenza-related
mortality in the elderly [50,51].
The most accepted immunological correlate of protection
is basedonhemagglutination inhibition (HAI) antibody (Box
2). Reviews of the humoral immune response to influenza
vaccines in the elderly have yielded conflicting results [53],
yet an impairment inHAI responses is believed to occur [54].
The large variation in humoral immunity induced by influ-
enza vaccines might be further complicated by so-called
‘original antigenic sin’, which describes how the specific
hemagglutinin and neuraminidase subtypes encountered
during primary influenza infection is thought to affect all
subsequent immune responses to the virus, particularly in
old age [55]. Elderly persons who meet the SENIEUR Pro-
tocol criteria had diminished responses to H1N1 but not
H3N2virus comparedwithyoungadults [56]; however, after
annually repeated vaccination, there was no difference be-
tween age groups [31]. Because the priming histories to
H3N2 were similar in the two age groups, it was suggested
that priming (previous exposures) from similar virus strains
might lead to increased heterotypic responses; viruses that
closely resemble each other result in a booster effect rather
than being recognized as new antigen and without booster
effect.
Theoretically, the decrease in quantity of antibody, as
measured by HAI, might be counterbalanced by an
increase in antibody avidity as a result of subsequent
vaccinations with the same antigen. However, over three
consecutive seasons, elderly subjects failed to demonstrate
a statistically significant increase in antibody avidity [57].
It has been suggested that the humoral response to influ-
enza vaccine declines more rapidly in the elderly, but this
postulate has also been questioned [58]. Therefore, the
effect of immunosenescence on the ability of the humoral
immune response to influenza vaccine to protect elderly
individuals remains unclear.
Box 1. Correlates of protection for pneumococcal vaccine
Finding a suitable immunological correlate of protection is crucial
for determining vaccine efficacy.
For pneumococcal vaccines, opsonization and phagocytosis of
pneumococci are the most accepted in vitro correlates, and this can
be determined by several techniques [40]:
(i) standard opsonophagocytosis (OPA) assay
(ii) killing-type OPA
(iii) phagocytosis of fluorescent bacteria by flow cytometry
(iv) uptake of radiolabeled bacteria
Box 2. Correlates of protection for influenza vaccine
‘Seroprotection’ in influenza is commonly defined as an hemagglu-
tination inhibition (HAI) antibody titer of 1:40, whereas ‘serocon-
version’ is the achievement of a fourfold increase in HAI titer after
immunization. However, laboratory-confirmed influenza infections
might still occur in the elderly even in the presence of HAI titers
1:640 [52]. Therefore, HAI titers are an imperfect correlate of
immunity, especially for the elderly. Functional measures of
antibody, such as virus neutralization, and qualitative measures,
such as antibody subclasses and avidity, provide additional means
to characterize the immune response to influenza vaccination.
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Protection from influenza infections and the elicitation
of humoral immunity requires an intact CMI response to
vaccination. It is probable that vaccine efficacy is a result of
a complex and carefully orchestrated interplay of multiple
factors within the immune system, and no single marker
sufficiently predicts vaccine responsiveness. Although T-
cell responses might not completely protect from infection,
antigen-specific T-cell proliferative responses and the
associated IL-2 and IFN-g production is impaired
[59,60], and protection is inversely associated with a shift
from Th1 cytokines (e.g. IFN-g) toward Th2 cytokines (e.g.
IL-10) dominance [61]. Elderly with lower levels of IL-6 at
the time of vaccination responded better to initial vaccina-
tion [32], perhaps reflecting a state of chronic inflam-
mation, termed inflammaging [62]. Lower granzyme B, a
key effectormechanism of influenza-specific cytotoxic T cell
(CTL)-mediated killing, was associated with laboratory
confirmed influenza [63]. Cytotoxic natural killer (NK) cell
activity has also been found to be associated with protec-
tion from all-cause respiratory tract disease and good HAI
response to influenza [64].
In conclusion, there is an urgent need to develop newer-
generation influenza vaccines to specifically address the
limitations of the current vaccines in protecting elderly
persons. One strategy to further protect the elderly is to
focus on the vaccination of young children, a common
pathway of respiratory virus transmission to the elderly.
Although the currently available influenza vaccines do not
optimally protect the elderly as a group, annual vaccina-
tion remains of outmost importance for public health and
for individuals who might indeed benefit from vaccination.
Tetanus, diphtheria, pertussis and tick-borne
encephalitis vaccines
Whereas influenza and pneumococcal disease are the most
frequently encountered infectious diseases in the elderly,
attention should also be paid to the prevention of less
frequent diseases such as tetanus, diphtheria, pertussis
or even tick-borne encephalitis (TBE). Although tetanus
infections have diminished dramatically since the tetanus
toxoid vaccine was introduced, the disease has not disap-
peared; in 2005, there were 27 tetanus cases in the Unites
States and 147 cases in the European Union (http://ec.
europa.eu/health/ph_information/dissemination/echi/docs/
tetanus_en.pdf). The elderly represent the main risk
group, both in terms of contracting these diseases and
dying from serious complications [65]. Furthermore there
was also a resurgence of diphtheria spread throughout the
Russian Federation in the early 1990s [66]. In Canada,
pertussis accounted for 16.2% of prolonged cough (1–8
weeks) in those 60 years old [67]. Adults have higher
rates of complications than adolescents, including pneu-
monia [68]. Immunity to vaccination against Bordotella
pertussiswanes after 5–10 years and rarely lasts>12 years
[69]. New acellular vaccines have been tested in persons
19–64 years of age [70], but their immunogenicity and
protective efficacy in persons >65 years of age remain
unknown.
Available combination vaccines for adults contain either
low-dose diphtheria toxoid with tetanus toxoid or both
compounds in combination with pertussis toxoid with or
without inactivated polio virus types 1/2/3. These vaccines
are relatively inexpensive and readily available in devel-
oped countries. They should be given at 10-year intervals
throughout life. TBE vaccines contain inactivated virus
and are recommended in areas where the disease is ende-
mic. TBE-endemic areas traverse Europe and include 27
European states.
Only a few studies have documented the number of
persons immunized and the efficacy of tetanus, diphtheria
and TBE vaccine in elderly persons [29,65,71–75]. These
studies demonstrate that vaccination coverage is low, and
failure to generate protective antibody concentrations is
frequent. Interestingly, the results were similar for both
SENIEUR compatible cohorts and patients in long-term
care facilities [72,29]. The protective antibody titer against
tetanus and TBE is dependent on both the time point of the
last vaccination and age; persons >60 years of age fre-
quently do not have protective antibody [74]. There are
only a few reports on CMI immunity against tetanus in
elderly persons [29,76]. The success of booster vaccinations
against tetanus, diphtheria and TBE also greatly depends
on prevaccination antibody concentrations; greater prevac-
cination antibody levels were associated with better
vaccine responses [75], suggesting that long-lived plasma
cells and memory B cells might also play an important role
in the maintenance of protective immunity.
Hepatitis B Vaccine
Safe and effective hepatitis B virus (HBV) vaccines have
been commercially available since 1981. Depending on the
country, licensed HBV vaccines currently available include
plasma-derived vaccines, prepared by harvesting particles
of hepatitis B surface antigen (HBsAg) protein from the
plasma of infected patients and recombinant DNA vaccines
produced in yeast or mammalian cells to generate the
HBsAg. There is a decline in frequency of anti-HBs
responses and a decrease in magnitude of anti-HBs titers
with each decade of life over the age of 40 years [77,78].
Even when adjusting for risk factors associated with poor
immune response, increasing age is an independent risk
for inadequate HBs antibody responses [79]. In terms of
seroconversion to HBsAg, a small study of ‘healthy geria-
tric patients’ showed that 69% of 61–70 year olds (n = 13),
44% of 71–80 year olds (n = 16) and only 39% of 81–96 year
olds (n = 41) seroconverted after three vaccine doses
injected at 1-month intervals [77]. These low seroconver-
sion rates contrast with the 96% seroconversion rates in
younger adult populations with the same vaccine. In two
meta-analyses, there was an increased risk of nonresponse
to HBV among healthy older individuals [80] and those
with end-stage renal disease on dialysis [81], respectively.
A combined effect of dysregulation of the B- and T-cell
compartments has been suggested as the cause of the
decreased anti-HBs antibody response [82].
In addition to age, several host attributes are epidemio-
logically associated with diminished responses to HBV
vaccines. These factors can coexist in persons of all ages,
including elderly persons, and confound the effects that are
the direct result of immunosenescence. One of these attri-
butes, somewhat theoretical, is that immunological toler-
ance or immunosuppression is induced by latent HBV
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infection (reviewed in Ref. [83]). A more recent hypothesis
is that cytomegalovirus (CMV), which establishes persist-
ent life-long infection, drives clonal expansion and alters
the phenotype and function of CD8 cells; such cellular
alterations in turn might account for the senescent
response to infections and vaccines [84–86]. A listing of
factors other than age that might contribute to diminished
immunity to hepatitis vaccination in the aged is given in
Box 3. Currently, all HBV vaccines licensed for human use
in the United States have been formulated with aluminum
salts, which are relatively weak adjuvants [97]. With a
view to improving HBV vaccines, an increasing array of
newer adjuvants are in phase 1–3 trials [98]. It remains to
be proven if new adjuvant formulations can induce vigor-
ous HBsAg antibody and CMI in elderly individuals
similar to that induced in healthy 18- to 40-year-old adults
[99].
Shingles vaccine
The shingles vaccine represents the rare success story of a
targeted vaccine for the elderly that has proven to be highly
effective. Another article in this special issue (Weksler
et al.) covers this story in more detail. We will therefore
only summarize by stating that, because the shingles
vaccine does not depend principally on the declining naı¨ve
T-cell population for priming immunity but rather on a
memory cell (booster) response, it would be expected that
immunesenescence plays a lesser role in the response to
this vaccine in the elderly. However, age still matters, as
illustrated by the decreasing efficacy of this vaccine seen in
80 year olds.
Other vaccines
Commercially available vaccines for other infectious
pathogens exist, including meningococcal, polio, measles,
mumps, rubella, polio, hepatitis A, yellow fever and rabies.
However, the burden of these particular diseases in the
elderly residing in the developed world is very low, and
therefore, routine vaccination of the elderly is not generally
recommended. However, these vaccines are offered to
elderly travelers to high-risk regions. The meningococcal
[100], rabies [101] and hepatitis A [102] vaccines are all
less immunogenic in the elderly. There is no published
information on the immunogenicity of the other vaccines
listed or on the protective efficacy of any of them in the
elderly. It is important to mention that vaccination with
the live-attenuated 17-D yellow fever virus vaccine can
rarely result in serious or fatal viscerotropic or neurotropic
disease, resulting from overwhelming systemic infection by
the 17-D vaccine virus, particularly in 60 year olds
receiving the vaccine for the first time [103,104]. Because
of space limitations, for additional details on travel
vaccines in the elderly, the reader is referred to a recent
review [102]. A summary of the vaccine trials that have
been performed in elderly populations highlights the pau-
city of data available, particularly regarding efficacy stu-
dies, is presented in Table 2.
Conclusions
The detrimental effects of aging on vaccination will
increase in importance as a public health concern in the
21st century. Despite the relative paucity of vaccine stu-
dies in the elderly, general agreement exists that the
immune response in the elderly is blunted and efficacy
is lower compared with healthy young adults for most
vaccines tested. In this chapter, we discussed some of
the immune perturbations that can be attributed to immu-
nosenescence. It is clear these immune defects need to be
Table 2. Current recommendations for vaccines in the elderly (age  65 years).
Vaccine Recommended frequency Studies in elderly Evidence of efficacy in the elderly Refs
Pneumococcal (PPV) Once at age 65 years + +/ [35,38,37]
Influenza 1 dose annually + +/ [46,45,1,47]
Tetanus, diphtheria 1 dose Td every 10 years + + [71–74,29]
Herpes Zoster Once at age 60 years + + [106]
Hepatitis B High-riska,b + + [107,82,108,81,80,78,79]
Measles, mumps, rubella High-riska,b – NA NA
Hepatitis A High-riska,b + NA [109,110]
Meningococcal High-risk1,2 + NA [100]
Japanese encephalitis Travelb +/ NA [111]
Typhoid (polysaccharide) Travelb – NA NA
Typhoid (oral, live) Travelb – NA NA
Polio Travelb – NA NA
Yellow fever Travelb – NA NA
Rabies Travelb +/ NA [112]
Cholera Travelb,c – NA NA
Tick-borne encephalitis Travelb,c + + [74]
Studies done in the elderly were as follows: +, done; +/, not specifically done in this age group; – not done.
The evidence of clinical efficacy in the elderly are as follows: +, clear, +/, not clear, NA, information not available based on the lack of specific studies in the elderly.
aHigh-risk situations include certain medical, occupational or lifestyle indications.
bTravel to areas with high endemic rates for the infection.
cVaccine not available in the United States.
Box 3. Confounding factors on hepatitis vaccination
Factors other than age that might contribute to diminished
immunity to hepatitis vaccination in the elderly:
 Human leukocyte antigen haplotypes [87,88]
 Protein-calorie malnutrition [89]
 Vitamin B12 [90].
 Vitamin E [91]
 Zinc and selenium [92].
 Other trace elements [93]
 Thyroid disease [94]
 Injection into fat rather than muscle [95]
 Low dosage [96]
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better characterized and overcome with next-generation
vaccines.
Animal studies are informative and provide guidance
for our understanding of the complexity of the human
immune response during aging (see article by Maue
et al. also in this issue). However, the unique nature of
the human immune system and the many confounding
variables that affect aged individuals call for caution in
interpreting animal data as a direct reflection of the mech-
anisms driving human immunosenescence. Indeed, we
have repeatedly observed experimental vaccine constructs
that worked well in animals, including nonhuman
primates, but that have not performed well in human
trials; importantly, these human trials were performed
with healthy young adults and not in the elderly. One
can predict that differences between animal and human
responses to vaccination will only become more pro-
nounced in the elderly.We fully concurwith a recent article
arguing that inbred mice can be used successfully as tools
for elucidating basic immunology but much less so as
models of disease [105]. This notion is equally applicable
to studies on immunosenescence, and in particular, on
vaccine development in the elderly. Ultimately, proof of
improved vaccines depends on clinical trials in elderly
cohorts. We are hopeful that, in the next few years, ger-
iatric vaccination will improve because of a better under-
standing of the mechanisms underlying human
immunosenescence leading to clinical trials of novel
vaccines, vaccine formulations, adjuvants and vaccine
delivery systems.
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